Autopsy report · NCT01972776

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

“Part 1 was completed. Part 2 was terminated for safety reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 48 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

COPD

Interventions

QBM076; Placebo

Participants

48

Sites

7

Countries

Germany, Romania, United Kingdom, United States

Trials that died the same way

• Physician's Comfort Level and Satisfaction Study With The e2TM Collector Compared to the Spatula/CytoBrush Technique
  “Terminated for lack of resources to complete.” (60% match in meaning)
• A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
  “Terminated due to safety concerns.” (59% match in meaning)
• Mortality Due to Malignancy in Patients With Idiopathic Venous Thromboembolism
  “Terminated because of futility to continue, after planned interim analysis.” (58% match in meaning)
• Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study
  “terminated due to administrative reasons.” (56% match in meaning)
• LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
  “Funding was terminated.” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.